[go: up one dir, main page]

MA33948B1 - Dérivés d'acide 3-hétéroaroylamino-propionique substitues par oxygène et leur utilisation en tant qu'agents pharmaceutiques. - Google Patents

Dérivés d'acide 3-hétéroaroylamino-propionique substitues par oxygène et leur utilisation en tant qu'agents pharmaceutiques.

Info

Publication number
MA33948B1
MA33948B1 MA35095A MA35095A MA33948B1 MA 33948 B1 MA33948 B1 MA 33948B1 MA 35095 A MA35095 A MA 35095A MA 35095 A MA35095 A MA 35095A MA 33948 B1 MA33948 B1 MA 33948B1
Authority
MA
Morocco
Prior art keywords
arilamino
substituted
oxygen
propionic acid
acid derivatives
Prior art date
Application number
MA35095A
Other languages
Arabic (ar)
English (en)
Inventor
Sven Ruf
Josef Pernerstorfer
Thorsten Sadowski
Georg Horstick
Herman Schreuder
Christian Buning
Thomas Olpp
Bodo Scheiper
Klaus Wirth
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MA33948B1 publication Critical patent/MA33948B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C229/36—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings with at least one amino group and one carboxyl group bound to the same carbon atom of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des composés de formule I, dans laquelle A, D, E, G, R
MA35095A 2010-01-26 2011-01-26 Dérivés d'acide 3-hétéroaroylamino-propionique substitues par oxygène et leur utilisation en tant qu'agents pharmaceutiques. MA33948B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10305080 2010-01-26
PCT/EP2011/051038 WO2011092187A1 (fr) 2010-01-26 2011-01-26 Dérivés d'acide 3-hétéroaroylamino-propionique à substitution oxygène et leur utilisation comme produits pharmaceutiques

Publications (1)

Publication Number Publication Date
MA33948B1 true MA33948B1 (fr) 2013-01-02

Family

ID=42035666

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35095A MA33948B1 (fr) 2010-01-26 2011-01-26 Dérivés d'acide 3-hétéroaroylamino-propionique substitues par oxygène et leur utilisation en tant qu'agents pharmaceutiques.

Country Status (30)

Country Link
US (2) US8664257B2 (fr)
EP (2) EP2826772A1 (fr)
JP (1) JP5736390B2 (fr)
KR (1) KR101764608B1 (fr)
CN (1) CN102884052B (fr)
AR (1) AR079967A1 (fr)
AU (1) AU2011209333B2 (fr)
BR (1) BR112012018253A2 (fr)
CA (1) CA2784571A1 (fr)
CL (1) CL2012002069A1 (fr)
CO (1) CO6660462A2 (fr)
DK (1) DK2528902T3 (fr)
ES (1) ES2530073T3 (fr)
HR (1) HRP20150075T1 (fr)
IL (1) IL220998A0 (fr)
MA (1) MA33948B1 (fr)
MX (1) MX2012008635A (fr)
MY (1) MY156569A (fr)
NZ (1) NZ601307A (fr)
PH (1) PH12012501284A1 (fr)
PL (1) PL2528902T3 (fr)
PT (1) PT2528902E (fr)
RS (1) RS53789B1 (fr)
RU (1) RU2561126C2 (fr)
SG (1) SG182659A1 (fr)
SI (1) SI2528902T1 (fr)
TW (1) TWI532725B (fr)
UY (1) UY33200A (fr)
WO (1) WO2011092187A1 (fr)
ZA (1) ZA201204414B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2766643C (fr) 2009-07-08 2017-01-03 Dermira (Canada), Inc. Analogues de tofa utile dans le traitement de troubles ou etats dermatologiques
JP5959075B2 (ja) 2011-05-31 2016-08-02 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー ネプリライシン阻害剤
CN103748070B (zh) 2011-05-31 2015-06-24 施万生物制药研发Ip有限责任公司 脑啡肽酶抑制剂
CA2835216A1 (fr) 2011-05-31 2012-12-06 Theravance, Inc. Inhibiteurs de neprilysine
KR20140049020A (ko) * 2011-07-26 2014-04-24 사노피 치환된 ３-（티아졸-４-카보닐）- 또는 ３-（티아졸-２-카보닐）아미노프로피온산 유도체 및 이의 약제로서의 용도
DK2736888T3 (da) 2011-07-26 2016-02-01 Sanofi Sa 3-heteroaroylaminopropionsyrederivater og deres anvendelse som farmaceutika
JO3215B1 (ar) 2012-08-09 2018-03-08 Phenex Pharmaceuticals Ag حلقات غير متجانسة بها 5 ذرات تحتوي على النيتروجين بها استبدال بكربوكساميد أو سلفوناميد كمعدلات لمستقبل نووي غير محمي RORy
WO2014053533A1 (fr) 2012-10-05 2014-04-10 Sanofi Utilisation de dérivés substitués de l'acide 3-hétéroaroylamino-propionique en tant que produits pharmaceutiques destinés à la prévention/au traitement de la fibrillation auriculaire
TW201514158A (zh) * 2013-03-28 2015-04-16 Sanofi Sa 二芳基－丙酸衍生物及其作為醫藥之用途
CN105073720B (zh) * 2013-03-28 2017-10-13 赛诺菲 联芳基‑丙酸衍生物及其作为药物的用途
WO2015060368A1 (fr) 2013-10-23 2015-04-30 武田薬品工業株式会社 Composé hétérocyclique
CN113332292A (zh) 2016-02-23 2021-09-03 辉瑞公司 6,7-二氢-5H-吡唑并[5,1-b][1,3]噁嗪-2-甲酰胺化合物

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD226883A1 (de) 1984-07-30 1985-09-04 Neubauer T Paedagog Hochschule Verfahren zur herstellung von 1,3-disubstituierten 5-alkoxy-1,2,4-triazolen und 1,2,4-triazolin-5-onen
US5258397A (en) 1988-11-30 1993-11-02 Novapharme 3-Isoxazoyl derivatives endowed with anticonvulsant activity, procedure for their preparation and their pharmaceutical compositions
JPH08510461A (ja) 1993-05-27 1996-11-05 シェル・インテルナチオナーレ・リサーチ・マートスハッペェイ・ベスローテン・フェンノートシャップ 除草性のチアゾール誘導体
JP2000169453A (ja) 1998-09-30 2000-06-20 Mitsubishi Chemicals Corp １―フェニルピラゾ―ル―３―カルボキサミド誘導体、その中間体およびこれを有効成分とする農薬
US20020173507A1 (en) 2000-08-15 2002-11-21 Vincent Santora Urea compounds and methods of uses
US20040072802A1 (en) 2002-10-09 2004-04-15 Jingwu Duan Beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha
JP4585448B2 (ja) 2002-12-23 2010-11-24 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 第Ｘａ因子阻害剤としてのピラゾール−誘導体
JP2005145839A (ja) 2003-11-12 2005-06-09 Japan Science & Technology Agency 新規なカテプシンａ阻害剤
EP1773768B8 (fr) * 2004-07-30 2018-12-26 Exelixis, Inc. Derives de pyrrole en tant qu'agents pharmaceutiques
AU2006205220B2 (en) 2005-01-10 2012-09-13 Exelixis, Inc. Heterocyclic carboxamide compounds as steroid nuclear receptors ligands
WO2007000582A1 (fr) 2005-06-28 2007-01-04 Takeda Cambridge Limited Antagonistes non-peptides heterocycliques de gnrh
CN101104602A (zh) * 2006-07-12 2008-01-16 赛诺菲-安万特 N-[(1,5-二苯基-1h-吡唑-3-基)甲基]磺酰胺衍生物其制备、用途
FR2908409B1 (fr) * 2006-11-10 2009-01-09 Sanofi Aventis Sa Pyrazoles substituees,compositions les contenant,procede de fabrication et utilisation
AR066268A1 (es) 2007-04-27 2009-08-05 Takeda Pharmaceutical Compuesto de imidazol sustituido y su uso
BRPI0822061A2 (pt) * 2007-12-10 2015-06-23 7Tm Pharma As Moduladores do receptor canabinoide
JP5504171B2 (ja) * 2007-12-26 2014-05-28 サノフイ Ｐ２ｙ１２アンタゴニストとしてのヘテロサイクリックピラゾール−カルボキサミド
EP2238127B1 (fr) 2007-12-26 2012-08-15 Sanofi Dérivés de pyrazole-carboxamide utiles en tant qu'antagonistes de p2y12
ATE555107T1 (de) 2008-02-21 2012-05-15 Actelion Pharmaceuticals Ltd 2-aza-bicyclo-ä2,2,1-üheptan-derivate
JP5420761B2 (ja) 2009-05-28 2014-02-19 ノバルティス アーゲー ネプリリシン阻害剤としての置換アミノプロピオン酸誘導体

Also Published As

Publication number Publication date
BR112012018253A2 (pt) 2023-11-21
CN102884052B (zh) 2015-10-21
KR101764608B1 (ko) 2017-08-03
PT2528902E (pt) 2015-01-14
ZA201204414B (en) 2013-02-27
JP2013518077A (ja) 2013-05-20
TW201130802A (en) 2011-09-16
JP5736390B2 (ja) 2015-06-17
IL220998A0 (en) 2012-09-24
MY156569A (en) 2016-03-15
US20130046004A1 (en) 2013-02-21
SG182659A1 (en) 2012-08-30
RS53789B1 (sr) 2015-06-30
MX2012008635A (es) 2012-08-23
RU2012136473A (ru) 2014-03-10
DK2528902T3 (en) 2015-02-09
KR20120118050A (ko) 2012-10-25
SI2528902T1 (sl) 2015-02-27
WO2011092187A1 (fr) 2011-08-04
AU2011209333A1 (en) 2012-08-09
EP2528902A1 (fr) 2012-12-05
PL2528902T3 (pl) 2015-04-30
TWI532725B (zh) 2016-05-11
HK1178538A1 (en) 2013-09-13
PH12012501284A1 (en) 2012-11-26
US8664257B2 (en) 2014-03-04
US20140128616A1 (en) 2014-05-08
NZ601307A (en) 2014-06-27
ES2530073T3 (es) 2015-02-26
HRP20150075T1 (hr) 2015-04-10
CL2012002069A1 (es) 2012-10-19
CA2784571A1 (fr) 2011-08-04
AU2011209333B2 (en) 2014-12-11
CO6660462A2 (es) 2013-04-30
EP2826772A1 (fr) 2015-01-21
UY33200A (es) 2011-08-31
EP2528902B1 (fr) 2014-11-12
AR079967A1 (es) 2012-02-29
RU2561126C2 (ru) 2015-08-20
CN102884052A (zh) 2013-01-16

Similar Documents

Publication Publication Date Title
MA33948B1 (fr) Dérivés d'acide 3-hétéroaroylamino-propionique substitues par oxygène et leur utilisation en tant qu'agents pharmaceutiques.
JOP20180103A1 (ar) مركب صيدلاني
UA108101C2 (xx) Похідні n3-заміщених n1-сульфоніл-5-фторпіримідинонів
EA201270216A1 (ru) Фармацевтический состав
EA201270257A1 (ru) Производные n1-сульфонил-5-фторпиримидинона
GEP20146197B (en) New compounds
ECSP11011411A (es) Derivados de prolina como inhibidores de catepsina
EA201270254A1 (ru) Производные 5-фторпиримидинона
UA108240C2 (uk) Похідні гексафторізопропілкарбамату, їх одержання і їх терапевтичне застосування
CR20130045A (es) Compuestos terapéuticos
MA33976B1 (fr) Spiroindolinone pyrrolidines
UA114087C2 (xx) Похідні піридину
UA110338C2 (xx) Хімічні сполуки
CR20130001A (es) Derivados de indolizina, su procedimiento de preparación y su aplicación en terapéutica
BR112015007310A2 (pt) compostos, composição farmacêutica, uso de um composto de fórmula (i) e uso de uma composição farmacêutica
EA201291217A1 (ru) ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ ПРОИЗВОДНЫЕ 1-(β-D-ГЛЮКОПИРАНОЗИЛ)-2-ТИЕНИЛМЕТИЛБЕНЗОЛА КАК ИНГИБИТОРЫ НЗПГ
EA201300388A1 (ru) Соединения замещенного бензамида
IN2014CN04530A (fr)
CR20120637A (es) Triazolopiridinas sustituidas
UA106889C2 (uk) Похідні n1-ацил-5-фторпіримідинону
CO6821935A2 (es) Derivados novedosos de cefalosporinas y cmposiciones farmacéuticas de estos
EA201270255A1 (ru) 5-фтор-2-оксопиримидин-1(2h)-карбоксилатные производные
EA201270256A1 (ru) Производные т1-замещенного 5-фтор-2-оксопиримидинон-1 (2h) -карбоксамида
MX340147B (es) Composiciones farmacéuticas y nutracéuticas del ácido abscísico.
UY32405A (es) Derivados de tiadiazoles y oxadiazoles, su preparacion y su aplicacion en terapia